Examining LAMP-2 Protein Changes in Older Adults
Study of the Evolution of the Expression of the LAMP-2 Protein During the Advance as Well as Variations and Allelic Mutations in the Main Genes Involved in the Occurrence of Age-related Myelodysplastic Syndromes
NA · Centre Hospitalier Universitaire de Nice · NCT06357923
This study is testing how the LAMP-2 protein changes in people over 60 to help us understand more about aging.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 60 Years to 99 Years |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Nice (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (Nice) |
| Trial ID | NCT06357923 on ClinicalTrials.gov |
What this trial studies
This study focuses on recruiting individuals over the age of 60 to investigate how the expression of the LAMP-2 protein evolves with aging. Participants will be recruited from a consultation or day hospital setting, ensuring a balanced male-to-female ratio. After obtaining consent, researchers will collect socio-demographic and medical data, followed by a peripheral venous blood sample for analysis. The goal is to better understand the biological markers associated with aging.
Who should consider this trial
Good fit: Ideal candidates for this study are men and women aged 60 and older.
Not a fit: Patients with a history of certain cancers or those unable to understand consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into aging processes and potential interventions to improve health outcomes in older adults.
How similar studies have performed: While studies on aging and protein expression exist, this specific focus on LAMP-2 protein evolution in older adults is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women over 60 years of age. Exclusion Criteria: * Inability to Understand Consent, * Non-Security Beneficiaries * social, subjects protected by law, subjects deprived of liberty, * history of breast cancer, * brain tumor, * melanoma, * colon cancer, * lung cancer, * prostate cancer, * lymphoma, * myeloma, * syndrome myelodysplastic/myeloproliferative, * leukemia, * history of radiation therapy.
Where this trial is running
Nice
- Chu de Nice — Nice, France (RECRUITING)
Study contacts
- Principal investigator: Andrea CICCONE — Centre Hospitalier Universitaire de Nice
- Study coordinator: Andrea CICCONE
- Email: ciccone.a@hu-nice.fr
- Phone: 0492034702
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Aging